Back to Browse Journals » HIV/AIDS - Research and Palliative Care » Volume 5

Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS

Authors Patel TS, Crutchley RD, Tucker AM, Cottreau J, Garey KW

Published Date July 2013 Volume 2013:5 Pages 153—162


Received 2 April 2013, Accepted 1 May 2013, Published 15 July 2013

Twisha S Pate, Rustin D Crutchley, Anne M Tucker, Jessica Cottreau, Kevin W Garey

Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX, USA

Abstract: Diarrhea is a common comorbidity present in patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) who are treated with highly active antiretroviral therapy. With a multifactorial etiology, this diarrhea often becomes difficult to manage. In addition, some antiretrovirals are associated with chronic diarrhea, which potentially creates an adherence barrier to antiretrovirals and may ultimately affect treatment outcomes and future therapeutic options for HIV. A predominant type of diarrhea that develops in HIV patients has secretory characteristics, including increased secretion of chloride ions and water into the intestinal lumen. One proposed mechanism that may lead to this type of secretory diarrhea is explained by the activation of the cystic fibrosis transmembrane conductance regulator and calcium-activated chloride channels. Crofelemer is a novel antidiarrheal agent that works by inhibiting both of these channels. The efficacy and safety of crofelemer has been evaluated in clinical trials for various types of secretory diarrhea, including cholera-related and acute infectious diarrhea. More recently, crofelemer was approved by the US Food and Drug Administration for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Results from the ADVENT trial showed that crofelemer reduced symptoms of secretory diarrhea in HIV/AIDS patients. Because crofelemer is not systemically absorbed, this agent is well tolerated by patients, and in clinical trials it has been associated with minimal adverse events. Crofelemer has a unique mechanism of action, which may offer a more reliable treatment option for HIV patients who experience chronic secretory diarrhea from antiretroviral therapy.

Keywords: crofelemer, HIV, antiretrovirals, secretory diarrhea

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Macular hole formation in a patient with Irvine-Gass syndrome: coincidence or rare complication?

Moschos MM, Gatzioufas Z, Rotsos T, Symeonidis C, Song X, Seitz B

Clinical Ophthalmology 2013, 7:1437-1439

Published Date: 15 July 2013

Impact of sociodemographic factors on cognitive function in school-aged HIV-infected Nigerian children

Boyede GO, Lesi FEA, Ezeaka VC, Umeh CS

HIV/AIDS - Research and Palliative Care 2013, 5:145-152

Published Date: 15 July 2013

A prospective study on postoperative pain after cataract surgery

Porela-Tiihonen S, Kaarniranta K, Kokki M, Purhonen S, Kokki H

Clinical Ophthalmology 2013, 7:1429-1435

Published Date: 15 July 2013

Management of asthma in the elderly patient

Melani AS

Clinical Interventions in Aging 2013, 8:913-922

Published Date: 15 July 2013

Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema

Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L, Turchetti P, Pacella F

Clinical Ophthalmology 2013, 7:1423-1428

Published Date: 16 July 2013

Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies

Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H, Simoff M, Li Q, Browning R, Turner FJ, Le Pivert P, Spyratos D, Zarogoulidis K, Celikoglu SI, Celikoglu F, Brachmann J

Drug Design, Development and Therapy 2013, 7:571-583

Published Date: 18 July 2013